| Field | Specification |
|---|---|
| Mfr No | |
| Product Type |
Overview
This product is a stable CRISPR knockout cell line in which Fkbp7 has been disrupted in the () background using CRISPR-Cas9 genome editing. It provides an isogenic model for loss-of-function studies of Fkbp7 in its native tissue context. Cells are supplied frozen (1×10⁶ cells / 1.0 ml, BSL-II) and grow as adherent monolayers.
CRISPR Knockout Design
- Target gene: Fkbp7
- Knockout strategy: CRISPR-Cas9–mediated frameshift-inducing INDEL generation; confirmed by sanger sequencing of frameshift-inducing indels
- Parental cell line: — , kidney origin
Gene Background
Fkbp7 is a protein-coding gene. Its encoded protein participates in cellular processes relevant to the biological pathways associated with cell biology. For detailed gene function, pathway context, and disease associations, refer to the NCBI Gene and UniProt entries for Fkbp7.
Cell Culture Specifications
- Culture medium
- DMEM, High Glucose + 10% FBS + 1% Penicillin/Streptomycin, 37°C, 5% CO₂
- Growth properties
- Adherent
- Tissue origin
- Organism
- Biosafety level
- BSL-II
- Format
- Frozen; 1×10⁶ cells / 1.0 ml
Quality is assessed by: Confirmed by Sanger Sequencing of frameshift-inducing INDELs.
Research Applications
- Validate Fkbp7 knockout by Western blot or qPCR versus the isogenic parental line.
- Investigate loss-of-function phenotypes: proliferation, viability, morphology, or pathway activity changes.
- Screen drug candidates targeting pathways regulated by Fkbp7 using this KO as an isogenic control.
- Perform rescue experiments by re-expressing wild-type Fkbp7 in the knockout background.
- Conduct transcriptomic or proteomic profiling comparing KO versus parental cells.
Important Notes
- Add selection antibiotic to culture medium only after the first passage post-thaw to allow cells to recover.
- Cell viability upon thaw is warranted for 30 days following shipment when handled per abm guidelines.
- For laboratory research use only. Not intended for diagnostic, therapeutic, or clinical applications.
Cell line sourcing and selection (species, tissue, and disease model matching) · Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA) · Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs) · Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles) · Inducible expression systems (Tet-On/Off and regulatable constructs) · Drug resistance marker selection (puromycin, G418, hygromycin, and others) · Custom growth and media optimisation for specific assay requirements · Scale-up production for high-throughput screening campaigns · Authentication and QC services (STR profiling, mycoplasma testing, viability assessment). Talk to a Scientist or contact support@biohippo.com.
